Impact of Prevnar 13 on Ear Infections in Children

Status:	Completed
Conditions:	Other Indications, Infectious Disease
Therapuetic Areas:	Immunology / Infectious Diseases, Other
Healthy:	No
Age Range:	Any - 18
Updated:	10/14/2017
Start Date:	December 2010
End Date:	December 2013

Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children

Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective
against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar.
It is expected that the effectiveness of Prevnar 13 against ear infections in children will
be similar to that observed following Prevnar. Pfizer has committed to conduct a
postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.

Inclusion Criteria:

- Case eligibility should be based on microbiologic data and should be reviewed and
documented by an appropriately qualified member of the investigator's study team
before cases are included in the study database.

- S pneumoniae identified from middle ear fluid or mastoiditis sample.

- Specimen obtained from children aged up to 18 years.

Exclusion Criteria:

- As this is an observational, laboratory based database study, there are no exclusion
criteria

We found this trial at

sites

Children's Hospital of Los Angeles - University of Southern California School of Medicine

Los Angeles, California 90027

from

Los Angeles, CA